I disagree - IMO it is a big deal as it signals a shift in focus from product development (the product being BOT) to sales - in other words now there is a company, now there are four potential products, so now the focus is on selling BOT!
My hopes:
Trial momentum will be maintained.
Posited "problem" of BTX 1503 repair inhibition will be addressed.
Fast-tracking BTX 1801 to a product will be attempted.
Melanoma only studied if resources not diverted from existing work.
Funding from big pharma without cramping Botanix' style (or worth).
I disagree - IMO it is a big deal as it signals a shift in focus...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 50026 | 4 |
View Market Depth
| Last trade - 09.33am 26/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable
